Allergy Therapeutics Record sales and a COVID-19 wildcard

Allergy Therapeutics plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) is an ultra-short-course subcutaneous allergy immunotherapy (SCIT) platform, which continues to make strong market share gains in a competitive environment. Several products using the PQ platform are in late-stage development in order to move them to full registration under new EU and US regulations. Another reassuring trading update states that the company has hit new records and has the resources in place to fund its pending R&D investment programme required to get its products approved by the regulators.

  • Strategy: AGY is a fully integrated pharmaceutical company focused on the treatment of allergies. There are three parts to its strategy: i) continued development of its European business via investment or opportunistic acquisitions; ii) the US PQ opportunity; and iii) further development of its pipeline.
  • Trading update: Sales in the past quarter were affected by the difficulty associated with patients attending hospitals during the COVID-19 lockdown. Despite this, June returned to “normal” and underlying sales in fiscal 2020 have grown 7% to £78.2m. AGY has strong gross cash of £37.0m to fund its future R&D investment.
  • COVID-19 test: With financial support from government and official institutions in Spain, AGY has invested into expanding its microbiological diagnostic facilities (AT Immunolab) to run COVID-19 tests. At full capacity, its real-time SARS-COV-2 test is expected to be able to perform 200,000 tests a year.
  • Risks: Over the next two years, AGY will be running several important clinical trials which, by their very nature, have binary outcomes. This is mitigated to some extent by the company’s long-standing experience. Forecasts must be viewed as provisional in the event of a second wave of the COVID-19 pandemic.
  • Investment summary: Despite COVID-19, Allergy Therapeutics has reported another record year for sales in fiscal 2020, with June reassuringly returning to “normal” levels. Operating efficiencies and the timing of R&D investment have led to a strong EBIT performance. AGY is trading on an EV/sales of only 0.80x 2021E, which, in our view, is too low for a company with a long and profitable product history, and well below the multiples commanded by its direct competitors.

DOWNLOAD THE FULL REPORT

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Hardman & Co

More articles like this

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be mild, like

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive Officer, Manuel

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards Agency (FSA),

Restaurant fined after peanut allergy teen suffered shock

A restaurant operator who served a curry containing nuts to a woman with an allergy has been fined. Eleanor Lincoln suffered anaphylactic shock after eating the takeaway for her 18th birthday in March 2021. She was treated in

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy restrictions too

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million at an

Online group supports parents coping with child allergies

A mother has set up a support group for parents coping with child allergies, offering them a “safe place to share”. Mother-of-two Claire Stone, from Thorndon, Suffolk, started Pippa Friendly to help other families in the same boat

Beware of ‘thunder fever

Doctors today warned asthmatics and hay fever sufferers face a higher risk of deadly allergic reactions due to the current thunderstorms. The combination of high pollen counts and wet weather creates a phenomenon known as ‘thunder fever’ or ‘thunderstorm

Allergies in children have risen seven-fold in past 15 years

Allergies in children have soared seven-fold in the last 15 years, new research shows. Now four in every ten children are allergic to something and scientists are still trying to understand what is causing the dramatic rise. Britain has

No more posts to show